Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial

British Journal of Dermatology

Volumn 178, Issue 1, 2018, Pages 114-123

  Langley, R G ^a   Tsai, T F ^b   Flavin, S ^c   Song, M ^c   Randazzo, B ^c   Wasfi, Y ^c   Jiang, J ^c   Li, S ^c   Puig, L ^d  

^a DALHOUSIE UNIVERSITY   (Canada)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; APREMILAST; CYCLOSPORINE; ETANERCEPT; ETRETIN; GUSELKUMAB; INFLIXIMAB; METHOTREXATE; TOFACITINIB; USTEKINUMAB; BIOLOGICAL PRODUCT; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY;

ABSCESS; ADULT; APPENDICITIS; ARTICLE; BACKACHE; BACTERIAL ARTHRITIS; BASAL CELL CARCINOMA; BILE DUCT CANCER; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DERMATOLOGY LIFE QUALITY INDEX; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPIDIDYMITIS; FEMALE; HEART INFARCTION; HUMAN; IMMUNOGENICITY; INFECTION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; OPEN STUDY; PANCREAS CARCINOMA; PERIODONTITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUVA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SALPINGITIS; SQUAMOUS CELL SKIN CARCINOMA; TRANSITIONAL CELL CARCINOMA; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; CLINICAL TRIAL; PATIENT-REPORTED OUTCOME; PSORIASIS; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PATIENT REPORTED OUTCOME MEASURES; PSORIASIS; TREATMENT OUTCOME; USTEKINUMAB;

EID: 85028508389     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.15750     Document Type: Article

References (23)

1. Parisi R, Symmons DP, Griffiths CE et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133:377–85.
2. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007; 445:866–73.
3. Yawalkar N, Tscharner GG, Hunger RE, Hassan AS. Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis. J Dermatol Sci 2009; 54:99–105.
4. Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol 2015; 27:127–33.
5. Stritesky GL, Yeh N, Kaplan MH. IL-23 promotes maintenance but not commitment to the Th17 lineage. J Immunol 2008; 181:5948–55.
6. Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371:1665–74.
7. Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371:1675–84.
8. Blauvelt A, Papp KA, Griffiths CE et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 2017; 76:405–17.
9. Griffiths CE, Reich K, Lebwohl M et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015; 386:541–51.
10. Langley RG, Elewski BE, Lebwohl M et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med 2014; 371:326–38.
11. Lebwohl M, Strober B, Menter A et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 2015; 373:1318–28.
12. Reich K, Armstrong AW, Foley P et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol 2017; 76:418–31.
13. Gordon KB, Blauvelt A, Papp KA et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 2016; 375:345–56.
14. Blauvelt A, Reich K, Tsai TF et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol 2017; 76:60–69.e9. https://doi.org/10.1016/j.jaad.2016.08.008
15. Gordon KB, Duffin KC, Bissonnette R et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med 2015; 373:136–44.
16. Fredriksson T, Pettersson U. Severe psoriasis–oral therapy with a new retinoid. Dermatologica 1978; 157:238–44.
17. Langley RG, Feldman SR, Nyirady J et al. The 5-point Investigator's Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat 2016; 26:23–31.
18. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19:210–16.
19. Mathias SD, Feldman SR, Crosby RD et al. Measurement properties of a patient-reported outcome measure assessing psoriasis severity: the psoriasis symptoms and signs diary. J Dermatolog Treat 2016; 27:322–7.
20. United States Department of Health and Human Services, Food and Drug Administration. Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products. U.S. Department of Health and Human Services, 2012.
21. McInnes IB, Kavanaugh A, Gottlieb AB et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013; 382:780–9.
22. Blome C, Gosau R, Radtke MA et al. Patient-relevant treatment goals in psoriasis. Arch Dermatol Res 2016; 308:69–78.
23. Strober B, Papp KA, Lebwohl M et al. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol 2016; 75:77–82.e7.